RT Journal Article
T1 Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases.
A1 Martínez-Chinchilla, Carlos
A1 Vazquez-Montero, Lucía
A1 Palazón-Carrión, Natalia
A1 Fernández-Román, Isabel M
A1 López-Barba, José
A1 de la Cruz-Merino, Luis
A1 Rodríguez-Baño, Jesús
A1 Palacios-Baena, Zaira R
K1 COVID-19
K1 SARS-CoV-2
K1 anti-CD20
K1 case report
K1 immunocompromised
K1 lymphoma
K1 rituximab
AB Immunosuppressant conditions such as hematological malignancies increase the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It has been described in the literature that patients on anti-CD20 maintenance therapies for lymphoid malignancies are susceptible to having recurrent flares together with viral replication or reinfections, although these cases are scarce. These patients are not well represented in randomized controlled trials, and as a consequence, the evidence for the use of certain treatments in this scenario is lacking. We present two cases of patients with B-cell lymphoma on remission and treated with rituximab on maintenance. They developed at least 1 flare of coronavirus disease 2019 (COVID-19) after acute infection and always after receiving rituximab. RT-PCR was positive in the nasopharyngeal swab and also in plasma. Patients were treated during flares with remdesivir, hyperimmune plasma, and corticosteroids. These two cases showed the unresolved problem of COVID-19 in immunosuppressant patients and showed that despite the vast amount of information available on SARS-CoV-2, information in this subgroup of patients is lacking.
YR 2022
FD 2022-04-14
LK http://hdl.handle.net/10668/20582
UL http://hdl.handle.net/10668/20582
LA en
DS RISalud
RD Apr 6, 2025